Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

• Hauptverfasser: Dongmei Wang (Verfasst von), Jieying Liu (Verfasst von), Ling Zhong (Verfasst von), Lu Ding (Verfasst von), Qian Zhang (Verfasst von), Miao Yu (Verfasst von), Ming Li (Verfasst von), Xinhua Xiao (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Metformin and pioglitazone monotherapy have been proven to alter gut microbiota in diabetes and obesity. The present study aimed to investigated whether the combined administration of pioglitazone and metformin achieved superior protective effects on high-fat diet (HFD)-fed obese mice and elucidated...